Bristol Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BRISTOL, and when can generic versions of BRISTOL drugs launch?
BRISTOL has one hundred and sixteen approved drugs.
There are fifty-five US patents protecting BRISTOL drugs.
There are one thousand six hundred and ninety-one patent family members on BRISTOL drugs in fifty-eight countries and three hundred and nine supplementary protection certificates in nineteen countries.
Summary for Bristol
International Patents: | 1691 |
US Patents: | 55 |
Tradenames: | 93 |
Ingredients: | 81 |
NDAs: | 116 |
Drug Master File Entries: | 1 |
Patent Litigation for Bristol: | See patent lawsuits for Bristol |
PTAB Cases with Bristol as patent owner: | See PTAB cases with Bristol as patent owner |
Drugs and US Patents for Bristol
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers Squibb | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-002 | Aug 1, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bristol Myers Squibb | COUMADIN | warfarin sodium | INJECTABLE;INJECTION | 009218-020 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bristol Myers Squibb | DELALUTIN | hydroxyprogesterone caproate | SOLUTION;INTRAMUSCULAR | 016911-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bristol | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-002 | Feb 8, 2013 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bristol Myers Squibb | MONOPRIL | fosinopril sodium | TABLET;ORAL | 019915-002 | May 16, 1991 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bristol
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-001 | Dec 27, 2005 | 8,589,188 | ⤷ Try a Trial |
Bristol Myers Squibb | SERZONE | nefazodone hydrochloride | TABLET;ORAL | 020152-004 | Dec 22, 1994 | 5,256,664*PED | ⤷ Try a Trial |
Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-002 | Dec 27, 2005 | 7,968,569 | ⤷ Try a Trial |
Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-005 | Dec 21, 2011 | 8,404,717 | ⤷ Try a Trial |
Bristol | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-003 | Feb 8, 2013 | 6,561,977 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BRISTOL drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 150 mg | ➤ Subscribe | 2014-02-03 |
➤ Subscribe | Capsules | 2.5 mg and 20 mg | ➤ Subscribe | 2016-07-12 |
➤ Subscribe | Injection | 10 mg/vial | ➤ Subscribe | 2013-11-05 |
➤ Subscribe | Capsules | 100 mg and 150 mg | ➤ Subscribe | 2010-03-19 |
➤ Subscribe | Tablets | 600 mg | ➤ Subscribe | 2009-04-09 |
➤ Subscribe | Nasal Spray | 4 mg/spray | ➤ Subscribe | 2016-07-15 |
➤ Subscribe | Tablets | 2.5 mg and 5 mg | ➤ Subscribe | 2016-12-28 |
➤ Subscribe | Tablets | 20 mg, 50 mg, 70 mg and 100 mg | ➤ Subscribe | 2010-06-28 |
➤ Subscribe | Tablets | 80 mg and 140 mg | ➤ Subscribe | 2011-06-17 |
➤ Subscribe | Delayed-release Capsules | 200 mg, 250 mg and 400 mg | ➤ Subscribe | 2004-06-01 |
➤ Subscribe | Capsules | 200 mg | ➤ Subscribe | 2006-09-25 |
➤ Subscribe | Capsules | 5 mg, 10 mg and 15 mg | ➤ Subscribe | 2010-08-30 |
➤ Subscribe | For Injection Suspension | 100 mg/vial | ➤ Subscribe | 2015-12-11 |
➤ Subscribe | Capsules | 300 mg | ➤ Subscribe | 2009-07-20 |
➤ Subscribe | Capsules | 200 mg | ➤ Subscribe | 2010-02-16 |
➤ Subscribe | Capsules | 50 mg, 100 mg and 200 mg | ➤ Subscribe | 2016-11-03 |
➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-06-14 |
➤ Subscribe | Tablets | 30 mg | ➤ Subscribe | 2005-06-01 |
➤ Subscribe | Tablets | 80 mg and 140 mg | ➤ Subscribe | 2011-06-16 |
➤ Subscribe | Capsules | 1 mg, 2 mg, 3 mg and 4 mg | ➤ Subscribe | 2017-02-08 |
➤ Subscribe | Capsules | 50 mg and 100 mg | ➤ Subscribe | 2006-12-18 |
➤ Subscribe | Capsules | 25 mg | ➤ Subscribe | 2010-07-12 |
International Patents for Bristol Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Slovenia | 3572416 | ⤷ Try a Trial |
European Patent Office | 2097078 | ⤷ Try a Trial |
New Zealand | 574805 | ⤷ Try a Trial |
Australia | 2003290651 | ⤷ Try a Trial |
Hong Kong | 1148274 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bristol Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1951684 | CA 2021 00011 | Denmark | ⤷ Try a Trial | PRODUCT NAME: FEDRATINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF ELLER ET FARMACEUTISK ACCEPTABELT HYDRAT DERAF, ISAER FEDRATINIB-DIHYDROCHLORIDMONOHYDRAT; REG. NO/DATE: EU/1/20/1514 20210209 |
2487162 | PA2016040,C2487162 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: KOBICISTATAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ARBA SOLVATAS IR DARUNAVIRAS,ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ARBA SOLVATAS, YPAC DARUNAVIRO ETANOLATAS; REGISTRATION NO/DATE: EU/1/14/967 20141119 |
1853250 | PA2014022 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: PACLITAXELUM; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220 |
2049522 | 524 | Finland | ⤷ Try a Trial | |
2498610 | CA 2020 00053 | Denmark | ⤷ Try a Trial | PRODUCT NAME: OZANIMOD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER OZANIMODHYDROCHLORIDE; REG. NO/DATE: EU/1/20/1442 20200525 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.